Elixinol WellnessASX:EXL Days Payable is 71.04 as of Dec. 2025, which is 36% below its 10-year median of 111.66. The stock has 7 warning signs investors should review. Among 923 Drug Manufacturers companies, Elixinol Wellness ranks worse than 61.76% on this metric.
The historical rank and industry rank for Elixinol Wellness's Days Payable or its related term are showing as below:
ASX:EXL'
s Days Payable Range Over the Past 10 Years
Min: 64.07 Med: 111.66 Max: 139.78
Current: 70.27
During the past 8 years, Elixinol Wellness's highest Days Payable was 139.78. The lowest was 64.07. And the median was 111.66.
ASX:EXL's Days Payable is ranked worse than 61.76% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs ASX:EXL: 70.27
Elixinol Wellness's Days Payable
declined
from Dec. 2024 (71.70) to Dec. 2025 (71.04).
It may suggest that Elixinol Wellnessaccelerated paying its suppliers.
Elixinol Wellness Days Payable Related Terms
Elixinol Wellness Days Payable Historical Data
* Premium members only.
The historical data trend for Elixinol Wellness's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EXL vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elixinol Wellness's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elixinol Wellness Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elixinol Wellness's Days Payable distribution charts can be found below:
* The bar in red indicates where Elixinol Wellness's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Elixinol Wellness's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elixinol Wellness (ASX:EXL) has a Days Payable of 71.04 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Elixinol Wellness and its competitors. This is 36% below median its historical median of 111.66. Over the past decade, Elixinol Wellness' Days Payable has ranged from 64.07 to 139.78. According to the industry distribution chart, Elixinol Wellness ranks #570 out of 923 companies in the Drug Manufacturers industry, placing it in the top 61.8%.
Is Elixinol Wellness' Days Payable too high?
Elixinol Wellness' current Days Payable of 71.04 is 36% below median its 10-year median of 111.66. Over the past 10 years, this metric has ranged from a low of 64.07 to a high of 139.78. The Drug Manufacturers industry median Days Payable is 90.98. Elixinol Wellness' value of 71.04 is 21.9% below this industry median. Based on the distribution chart, Elixinol Wellness ranks #570 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Elixinol Wellness' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Elixinol Wellness ranks #570 out of 923 companies for Days Payable. This places Elixinol Wellness in the lower half of its industry. The industry median Days Payable is 90.98. Elixinol Wellness' value of 71.04 is 21.9% below this benchmark. Historically, Elixinol Wellness' own Days Payable has ranged from 64.07 to 139.78 over the past decade. While the company's 10-year median is 111.66 vs. the industry median of 90.98, Elixinol Wellness has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elixinol Wellness's current Days Payable of 71.04 is 21.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Elixinol Wellness and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elixinol Wellness's current Days Payable is 71.04, which is 36% below median its own 10-year median of 111.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elixinol Wellness stock overvalued right now?
Based on GuruFocus' analysis, Elixinol Wellness (ASX:EXL) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 70% below its estimated fair value. The current Days Payable is 71.04, which is 36% below median its 10-year median of 111.66 and 21.9% below the Drug Manufacturers industry median of 90.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Elixinol Wellness (ASX:EXL), the current Days Payable is 71.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Elixinol Wellness Ltd is engaged in the hemp industry, innovating, marketing, and selling hemp-derived nutraceutical, cosmetic, and food products. It operates in the three operating segments of the Americas, Australia, Rest of the World regions of which key revenue is derived from the Australia segment. The Australia segment includes the results from operations of Elixinol Wellness (Byron Bay) Pty Ltd and The Sustainable Nutrition Group Pty Ltd and its subsidiaries. It derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EXL has been successfully added to your 